Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00030498 · ClinicalTrials.gov registry record · Phase 1
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 75
- Enrollment target
NCT00030498: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00030498 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 75 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00030498, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 75 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
Interventions
- OTHER laboratory biomarker analysis
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2001-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00030498
The ClinicalTrials.gov registry entry for NCT00030498 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00030498 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00030498 about?
NCT00030498 is a clinical study titled "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction". Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction. Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor
What is the current status of trial NCT00030498?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2001-12.
What interventions are being tested in trial NCT00030498?
The interventions under investigation include: laboratory biomarker analysis (OTHER), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00030498?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.